Sclerostin antibody (Scl-Ab) increases osteoblast activity, in part through increasing modeling-based bone formation on previously quiescent surfaces. Histomorphometric studies have suggested that this might occur through conversion of bone lining cells into active osteoblasts. However, direct data demonstrating Scl-Ab-induced conversion of lining cells into active osteoblasts are lacking. Here, we used in vivo lineage tracing to determine if Scl-Ab promotes the conversion of lining cells into osteoblasts on periosteal and endocortical bone surfaces in mice. Two independent, tamoxifen-inducible lineage-tracing strategies were used to label mature osteoblasts and their progeny using the DMP1 and osteocalcin promoters. After a prolonged "chase" period, the majority of labeled cells on bone surfaces assumed a thin, quiescent morphology. Then, mice were treated with either vehicle or Scl-Ab (25 mg/kg) twice over the course of the subsequent week. After euthanization, marked cells were enumerated, their thickness quantified, and proliferation and apoptosis examined. Scl-Ab led to a significant increase in the average thickness of labeled cells on periosteal and endocortical bone surfaces, consistent with osteoblast activation. Scl-Ab did not induce proliferation of labeled cells, and Scl-Ab did not regulate apoptosis of labeled cells. Therefore, direct reactivation of quiescent bone lining cells contributes to the acute increase in osteoblast numbers after Scl-Ab treatment in mice.
Introduction
O steoblasts ultimately undergo one of three fates: They can die by apoptosis, become ensconced within mineralized matrix as osteocytes, or remain quiescent on bone surfaces as bone lining cells. (1, 2) Osteoporosis therapies that increase osteoblast activity may do so by multiple potential mechanisms; one rapid pathway to increase bone formation by osteoblasts is via direct conversion of quiescent bone lining cells into active osteoblasts. This pathway has long been posited to be important for how intermittent parathyroid hormone (PTH) treatment rapidly increases osteoblast numbers. (3) We recently employed lineage tracing to prove that intermittent PTH administration converts the phenotype of quiescent lining cells to that of active bone-forming osteoblasts. (4) Sclerostin, encoded by the SOST gene, is an osteocyte-derived negative regulator of bone formation. (5) Mutations in or near SOST are responsible for the human skeletal dysplasias sclerosteosis and Van Buchem disease, (6, 7) and common polymorphisms in SOST have been linked to bone density variation and fracture risk through genome-wide association studies. (8, 9) Acting as a canonical WNT pathway inhibitor, sclerostin tonically inhibits bone formation by osteoblasts. (10) Manipulations, such as mechanical loading (11) and treatment with intermittent PTH, (12) that increase bone f o r m a t i o nd os oi np a r tb yr e d u c i n gS O S Te x p r e s s i o nb y osteocytes. (13, 14) However, the precise molecular and cellular mechanisms through which sclerostin controls osteoblast differentiation and function remain incompletely understood.
Sclerostin antibody (Scl-Ab) has emerged as a promising therapeutic option for the treatment of osteoporosis. Scl-Ab administration results in activation of bone formation in rodents, cynomolgus monkeys, and humans. (15) (16) (17) (18) Scl-Ab dramatically increases bone formation on previously quiescent surfaces, so-called modeling-based bone formation, in rats and cynomolgus monkeys. (19) The initiation of modeling-based bone formation by Scl-Ab either occurs through recruitment of new osteoblasts to a quiescent surface or by direct activation of previously quiescent bone lining cells. Indeed, stereologic histomorphometric analyses have demonstrated concomitant decreases in lining cells and increases in osteoblasts after Scl-Ab treatment in rat trabecular bone. (20) However, this methodology does not definitively prove conversion of lining cells into active osteoblasts, nor does it reflect the effects of Scl-Ab in cortical bone. To better understand the possible effects of Scl-Ab on lining cell activation, we conducted a lineage-tracing study in mice to label lining cells before administration of Scl-Ab and examine their subsequent fate.
Materials and Methods

Mice
Temporally controlled transgene expression was used to trace cells of the osteoblast lineage using Dmp1-CreERt2 and Rosa26R mice as previously described. (4, 21) Dmp1-CreERt2 mice were crossed with Rosa26R mice in which expression of Escherichia coli b-galactosidase can be induced by Cre-mediated recombination using a universally expressed promoter. (22) These studies were approved by the Institutional Animal Care and Use Committee of Seoul National University. Male and female mice were used for these studies. Osteocalcin-CreERt2 mice (23) were crossed with B6.Cg-Gt(ROSA)26Sor tm9(CAG-tdTomato)Hze I (Ai9) tdTomato reporter mice (24) from the Jackson Laboratory (Bar Harbor, ME, USA) and osteocalcin-GFP mice. (25, 26) These studies were approved by the Massachusetts General Hospital IACUC. Female mice were used for studies with osteocalcin-CreERt2 mice. Animals were housed together, fed standard chow, and kept under 12-hour light/dark cycles. Genotyping primers and protocols are available upon request.
Tamoxifen administration
For experiments with DMP1-CreERt2:Rosa26R mice, 4-hydroxytamoxifen was used. For 4-OHTam injections, 2.5 mg of 4-OHTam (Takeda, Osaka, Japan) was dissolved in 100 mLo f dimethylformamide (Thermo Fisher Scientific, Waltham, MA, USA) and then diluted to 2.5 mg/mL in corn oil (Sigma, St. Louis, MO, USA). Dmp1-CreERt2:Rosa26R mice were injected with 0.5 mg 4-OHTam on postnatal weeks 4, 5, 6, 7, and 8.
For experiments with osteocalcin-CreERt2:Ai9 mice, mice were injected with 1.0 mg tamoxifen on postnatal week 10. Tamoxifen (Sigma, T5648) was dissolved in 100% ethanol. This solution was mixed with an equal volume of sunflower seed oil (Sigma, S5007) and incubated at 60°C overnight in a chemical hood until the ethanol completely evaporated. The tamoxifenoil mixture was then stored at room temperature until use.
Sclerostin antibody administration
Mice were injected subcutaneously with vehicle (phosphatebuffered saline) or 25 mg/kg sclerostin antibody (ratized Scl-Ab; Amgen Inc., Thousand Oaks, CA, USA; UCB, Brussels, Belgium) twice over the course of a week. For experiments with DMP1-CreERt2:Rosa26R mice, Scl-Ab was administered 4 weeks after the last tamoxifen treatment (age 12 weeks). For experiments with osteocalcin-CreERt2:Ai9 mice, vehicle or Scl-Ab was administered 5 weeks after the last tamoxifen treatment (age 15 weeks). Mice were randomly allocated into each treatment group.
Histology, X-gal staining, and cell thickness measurement X-gal staining for b-galactosidase activity was performed on sections from DMP1-CreERt2:Rosa26R mice as reported previously. (27) Briefly, calvaria and long bones were dissected from the mice, and all soft tissues were removed. Each sample was rinsed twice with PBS, fixed in 10% formalin for 30 minutes at 4°C, washed three times with PBS, and then stained overnight at 37°C in X-gal solution containing 1 mg/mL X-gal (Takeda, Osaka, Japan), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl 2 , 0.01% sodium deoxycholate, and 0.02% Nonidet P-40. Samples were decalcified with buffered EDTA for 2 weeks and then embedded and processed for paraffin sectioning. Sections were counterstained with eosin. X-gal (þ) cells were examined using 3 to 4 comparable sections and 9 to 12 fields from each section under 400Â from variable numbers of mice per experiment, as indicated in the figure legends. Periosteal X-gal (þ) cells from each femur were analyzed using Leica Application Suite camera (Leica Microsystems, Buffalo Grove, IL, USA; DM 2500) and software (LAS V3.8).
Detection of tdTomato and cell thickness measurement Soft tissue from tibias was removed and bones were fixed in 4% paraformaldehyde overnight at 4°C, then decalcified in 15% EDTA for 21 days. Decalcified samples were cryoprotected in 30% sucrose/PBS solutions and then in 30% sucrose/PBS:OCT (1:1) solution overnight at 4°C. Samples were embedded in OCT compound (TissueTek, Sakura Finetek USA, Torrance, CA, USA) and transferred onto a sheet of dry ice. Embedded samples were cryosectioned at 15 mm using a cryostat (Leica CM1850). Images were captured with a wide-field fluorescence microscope (Nikon Eclipse E800) using triple-band filter setting for DAPI/FITC/TRITC, and merged with Spot Advanced Software. Confocal images were acquired using LSM510 software (Zeiss, Jena, Germany) with lasers and bandwidth filters for DAPI (excitation 405 nm, BP420-480), GFP (excitation 488 nm, BP505-530), tdTomato (excitation 543, BP565-595), and Alexa633 (excitation 633 nm, LP650). LSM Image Viewer software was used to capture images, and Adobe Photoshop was used to align images. Representative images from groups including least five independent biological samples are shown in the figures.
For experiments with osteocalcin-CreERt2:Ai9 mice, highpower (400Â) confocal images of all tomato-positive cells on endosteal surfaces on three sections per mouse were obtained. Images were coded and imported into ImageJ and thickness measured in the orientation perpendicular to the bone surface. All measurements were made by an observer blinded to the experimental conditions.
BrdU/EdU labeling and detection
For experiments with DMP1-CreERt2:Rosa26R animals, mice were injected intraperitoneally with BrdU (5-bromo-2-deoxyuridine, Sigma) at 8-hour intervals for 24 hours and were euthanized 6 hours after the last injection. Tissues were fixed in 4% (vol/vol) paraformaldehyde, processed, and sectioned by standard procedures. BrdU incorporation into DNA was detected using an anti-BrdU antibody staining kit (Zymed Laboratories, San Francisco, CA, USA). The BrdU labeling index was calculated as the ratio of BrdU-positive nuclei relative to the total nuclei on the corresponding periosteal surface of four independent sections of the femur from four mice.
For experiments with osteocalcin-CreERt2:Ai9 animals, mice were injected with 1 mg 5-ethynyl-2'-deoxyuridine (EdU; Invitrogen, Carlsbad, CA, USA; A10044) in PBS 4 hours before euthanization. Click-iT imaging kit (Invitrogen C10337) with Alexa Fluor 647-azide was used to detect EdU in cryosections.
Caspase-3 and CD45 Immunohistochemistry
Cryosections were stored at -20°C until use. Sections were postfixed in 4% paraformaldehyde for 15 minutes at room temperature. Sections were then stained with an antibody recognizing cleaved caspase 3 (Cell Signaling, Danvers, MA, USA; 5A1E, #9664) and CD45 (BD Pharmingen, San Diego, CA, USA; 30-F11, #550539) following the manufacturer's instructions. An Alexa 647 goat anti-rabbit secondary antibody was used for detection, and sections were stained with DAPI before analysis.
Serum biochemistry
Blood was collected by orbital sinus puncture before animals were euthanized. Serum levels of the N-terminal propeptide of type I procollagen (P1NP) was measured with ELISA kits from Immunodiagnostic Systems (Fountain Hills, AZ, USA).
Electron microscopic analysis and measurement of cell thickness
For experiments with DMP1-CreERt2:Rosa26R mice, after X-gal staining, calvaria were cut transversely at the mid-sagittal suture, fixed in 2.5% glutaraldehyde, 2.0% paraformaldehyde, and 0.025% calcium chloride in 0.1 M sodium cacodylate buffer (pH 7.4), and processed for electron microscopy (EM). The LacZpositive cells were identified by the deposits of X-gal reaction product in the cytoplasm, which appeared as a heterogeneously distributed black amorphous material. (28) Samples were examined with a JSM-7401F scanning EM (JEOL, Tokyo, Japan).
Statistics
All data are presented as mean AE standard error of mean (SEM) as indicated in the figure legends, except for serum P1NP measurements, which are shown as mean AE standard deviation (SD). The statistical significance of differences between groups was determined by Student's t test or ANOVA. Any p values < 0.05 were accepted as significant.
Results
Scl-Ab treatment acutely increases the thickness of periosteal lacZþ osteoblast descendants
First, we sought to determine if Scl-Ab administration, like intermittent PTH, can activate quiescent periosteal bone lining cells. The Dmp1-CreERt2 transgene is active in osteocytes and a subset of osteoblasts on the surfaces of calvariae and long bones. (4, 21, 29) In this system, administration of 4-OHTam induces transient nuclear translocation and CreERt2-mediated gene recombination. Because 4-OHTam activity is detected for only 24 hours post-injection, (28) this inducible system allows us to mark CreERt2-expressing cells and their descendants genetically and at a particular time. The number and thickness of the X-gal (þ) cells on the periosteal surface of the bones was quantified 2 days (8w) and 4 weeks (12w) after the last 4-OHTam injection, respectively, and after Scl-Ab (13w_Scl-Ab) or vehicle (13w_vehicle) treatment. Four to six comparable sections from the bones were selected, and the number and the thickness of X-gal (þ) cells were measured. The apparent number of X-gal (þ) cells on the periosteal surface of the femur was markedly higher in mice treated with Scl-Ab for 1 week than in mice at 4 weeks after the last 4-OHTam injection and in vehicle-treated mice (Fig. 2B) . Furthermore, Scl-Ab markedly increased the thickness of osteoblastic descendants in the periosteum of the femur compared with the thickness before Scl-Ab treatment. (Fig. 2C ).
Scl-Ab treatment increases the osteoblast activity but not proliferation rate on the periosteal surface of the femur As expected, 1 week of Scl-Ab treatment increased serum levels of P1NP compared with vehicle (Fig. 3A) . The observed increase in X-gal (þ) cells we observed (Fig. 2B) was not necessarily predicted. To explore the mechanism of this increase, we performed BrdU incorporation assays. Scl-Ab did not increase BrdU incorporation into periosteal X-gal (þ) cells (Fig. 3B, C) . As a positive control for BrdU labeling, robust staining of small intestine from the same mice is shown in Supplemental Fig. S1 . Collectively, these data support the hypothesis that Scl-Ab reactivates quiescent lining cells on the periosteal surface to become active osteoblasts. We do not fully understand the mechanisms underlying the apparent Scl-Ab-mediated increase in periosteal X-gal (þ) cell numbers; possibilities to account for this phenomenon are reviewed in the Discussion.
Scl-Ab converts quiescent lining cells to active osteoblasts: ultrastructural criteria
Ultrastructural features of the cells lining the periosteal surface were determined by electron microscopy. EM analysis was performed on transverse sections of the calvaria. Consecutive sections were examined by light microscopy and EM. As shown in Fig. 4 , EM of X-gal (þ) cells on the periosteal surface of the calvaria from Dmp1-CreERt2:Rosa26R mice 4 weeks after the last 4-OHTam injection (12w) showed the typical morphology of inactive lining cells, with scant endoplasmic reticulum. Scl-Ab resulted in an apparent increase in cell size and in the abundance of intracellular organelles, many of which appeared to be rough endoplasmic reticulum ( Fig. 4 ; 13w_Scl-Ab). X-gal deposits were observed in the cytoplasm and appeared as randomly distributed black amorphous microcrystalline structures. In contrast, X-gal deposits were not observed in osteoblasts on bone surfaces of Rosa26R mice lacking the Dmp1-CreERt2 transgene (Supplemental Fig. S2) . Thus, the EM analysis supports the hypothesis that short-term SclAb treatment activates lining cells to differentiate into cuboidal osteoblasts that may have robust capacities for protein synthesis.
A lineage tracing system to label endocortical osteoblasts The DMP1-CreERt2;Rosa26R system allows for robust identification and lineage tracing of periosteal osteoblasts. (4) However, few endocortical and cancellous osteoblasts are labeled using this strain. This may reflect limited penetration of the X-gal staining solution. In addition, X-gal staining typically leads to high-background, low-intensity signals, difficulty delineating cell boundaries, and an inability to use confocal microscopy for subsequent analysis. To circumvent these problems, we used an osteocalcin-CreERt2 strain (23) in combination with a conceptually similar Cre-dependent tdTomato reporter strain, termed Ai9. (24) Here, X-gal staining is not required for detection of Credependent tdTomato expression. As previously reported, (23) 2 days after tamoxifen administration, tdTomato expression is easily detectable in osteoblasts on cancellous and endocortical surfaces in tibia of such animals (Supplemental Fig. 3A) . Importantly, in the absence of tamoxifen, tdTomato expression is not present in these mice (Supplemental Fig. 3B ).
After chase periods of >4 weeks after tamoxifen administration, the vast majority of tdTomato-positive cells present on bone surfaces had disappeared. However, rare tdTomatopositive cells persisted on endocortical surfaces with a thin, quiescent morphology (Supplemental Fig. 3C, D) . Quantification of the thickness of these cells demonstrated a significant reduction compared with those endocortical tdTomato-positive cells present 2 days after tamoxifen administration (Supplemental Fig. S3E ). We were unable to reliably detect persistent tdTomato-positive cells on cancellous bone surfaces in the tibia after prolonged chase ( 4 cells/section) in these mice. Therefore, this osteocalcin-CreERt2:Ai9 lineage-tracing system allows for the study of endocortical bone lining cells. Because Scl-Ab increases modeling-based bone formation and reduces quiescent surfaces at endocortical sites in cynomolgus monkeys, (19) we used this system to assess effects of Scl-Ab on murine genetically labeled endocortical bone lining cells.
Short-term Scl-Ab treatment increases the number and thickness of tdTomatoþ osteoblast descendants on the endocortical surface of the tibia Fig. 5 shows the experimental strategy used to assess the effects of Scl-Ab treatment on endocortical bone lining cells. A cohort of female mice were treated with tamoxifen once at age 10 weeks. Six mice were euthanized 5 weeks later. The remaining 12 mice were either treated with vehicle or Scl-Ab (25 mg/kg) twice over the course of the subsequent week. All animals were treated with EdU 4 hours before death to label dividing cells.
As expected, 1 week of Scl-Ab treatment significantly increased serum P1NP levels (Fig. 6A) . Representative images showing the tdTomato-positive cells on endocortical bone surfaces in the various treatment groups are shown in Fig. 6B .In the 5wk and 6wkþVEH groups, tdTomato-positive osteocytes are observed, along with rare, thin cells present on endocortical surfaces. In contrast, in the 6wkþScl-Ab group, many plump tdTomato-positive cells are present on bone surfaces. The thicknesses of all endocortical tdTomato-positive cells on 2 tibia sections/mouse were measured for all 18 experimental animals. As shown in Fig. 6C , the majority of tdTomato-positive cells in the 5wk and 6wkþVEH groups were quite thin (each data point in the figure represents an individual measured cell). In contrast, cells measured after Scl-Ab treatment appeared thicker, with few thin cells remaining. Mouse #9 in the 6wkþVEH group appeared to have many thick cells and also showed higher serum P1NP levels. Fig. 6D shows the average cell thickness for each mouse across the experimental groups. Scl-Ab treatment significantly increased the average cell thickness measured. Fig. 6E shows the relationship between average cell thickness and serum P1NP across the three different groups of experimental mice. Animals with the most robust serum P1NP response also tended to show a more dramatic increase in tdTomato-positive cell thickness. These results are consistent with the hypothesis that lining cell reactivation contributes to Scl-Ab-mediated increases in bone formation in these mice.
Osteocalcin-CreERt2:Ai9 mice were crossed to an osteocalcin-GFP transgenic reporter strain. (25) This strategy affords distinction between cells currently expressing osteocalcin (GFPþ) and cells that expressed osteocalcin at one time in their life span (tdTomatoþ). Some of the mice used for these experiments were positive for all three transgenes (osteocalcin-CreERt2, Ai9, and osteocalcin-GFP). 
Scl-Ab increases lining cell reactivation without affecting proliferation or apoptosis
Similar to results observed in DMP1-CreERt2:Rosa26R mice, SclAb appeared to increase the numbers of visible tdTomatopositive cells on bone surfaces of osteocalcin-CreERt2:Ai9 mice. Therefore, we investigated whether this increase in cell number was a consequence of the effects of Scl-Ab proliferation and/or apoptosis. EdU was administered to all mice before euthanization to label proliferating cells. Although robust EdU incorporation was noted in bone marrow cells, cells positive for both EdU and tdTomato were not observed in any of the Scl-Ab-treated mice (Fig. 8A) . Immunostaining for activated Caspase 3 (aCasp3), a hallmark of cells undergoing apoptosis, (30) was performed to determine if Scl-Ab treatment regulates apoptosis of tdTomato-labeled lining cells. Although aCasp3-positive cells were present in the bone marrow and growth plate, no aCasp3/tdTomato double-positive cells were observed in any of the 18 mice studied here (Fig. 8B for representative  images) . Therefore, apoptosis is not a prominent feature of bone lining cells at steady state, so reduced apoptosis is unlikely to solely account for Scl-Ab-mediated lining cell reactivation.
Tamoxifen-dependent labeling of bone marrow stromal cells in osteocalcin-CreERt2:Ai9 mice In the course of these studies, we repeatedly noted the presence of tdTomato-positive cells with a particular reticular appearance in the bone marrow far from bone surfaces. Representative images of their morphologic characteristics are shown in Supplemental Fig. S4A . These cells are nonproliferating (Supplemental Fig. S4B ) and do not express the hematopoietic marker CD45 (Supplemental Fig. S4C) .
A recent report using the same Cre-dependent Ai9 tdTomato reporter with constitutive osteocalcin-Cre and DMP1-Cre transgenes demonstrated tdTomato-positive bone marrow reticular cells as well. (31) Zhang and Link reported that many of these tdTomato-positive bone marrow stromal cells expressed high levels of a GFP transgene under the control of the CXCL12 promoter, a well-described marker of perivascular stromal cells implicated in mesenchymal/ hematopoietic cross-talk. (32) Notably, CXCL12-GFP abundant reticular (CAR) cells may represent an osteoblast precursor population. (33) Therefore, the possibility remains that Scl-Ab might increase tdTomato-positive endocortical osteoblasts by recruiting labeled stromal cells to become osteoblasts rather than by reactivating previously quiescent bone lining cells. However, overall numbers of tdTomato-positive bone marrow cells with reticular morphology away from bone surfaces was not affected by Scl-Ab treatment (Supplemental Fig. S4D ), and conversion of marrow stromal cells to osteoblasts would not explain the diminished number of lining cells observed after Scl-Ab treatment. Although not definitive, these data argue that the most likely mechanism through which Scl-Ab increases tdTomato-positive osteoblasts is through lining cell reactivation.
Discussion
Here we used lineage tracing to show that Scl-Ab can stimulate bone lining cells to become active osteoblasts in vivo. These results extend previous stereological data demonstrating reduced numbers of quiescent lining cells and concomitant increases in osteoblast numbers in response to Scl-Ab. (19, 20) Using two independent models to label mature osteoblasts and their descendants, here we observe that Scl-Ab administration rapidly increases the thickness of labeled cells on periosteal and endosteal cortical surfaces. The most likely mechanism accounting for these findings is that sclerostin neutralization causes quiescent lining cells to reacquire an osteoblastic phenotype. An implication of this finding is that a physiologic role of tonic sclerostin action in bone may be to maintain lining cells on inactive bone surfaces in a quiescent state. Because intermittent PTH also reactivates lining cells and lowers sclerostin levels in bone, (12) it is possible that PTHmediated lining cell reactivation could occur via reducing sclerostin production by osteocytes.
The molecular mechanisms underlying Scl-Ab-mediated lining cell reactivation remain incompletely understood. Recent transcriptional profiling data on bone cells (osteoblasts, lining cells, and osteocytes) after Scl-Ab treatment may provide some clues. (34, 35) For example, lining cells (defined as cells on bone surfaces where fluorochrome label was absent) show rapid activation of canonical WNT target genes and ECM components after Scl-Ab treatment. Future studies will be required to understand how activation of WNT signaling rapidly converts lining cells into osteoblasts.
We acknowledge two important limitations in our study. First, the labeling strategies we have employed are designed to label only a small fraction of all osteoblasts and their lining cell descendants. Therefore, it is impossible for us to determine what percentage of all osteoblasts activated by Scl-Ab derive from bone lining cells versus other sources. Second, we use cell thickness as a proxy measure to assess osteoblast activation. Our current study design did not include simultaneous tetracycline labeling to assess proximity of thick, labeled cells to active bone surfaces. In previous studies, we have shown that thick, labeled cells on bone surfaces actively express type I collagen mRNA. (4) Importantly, work by Kalajzic and colleagues using a similar approach has shown that thick, labeled cells are more likely to be near active, tetracycline-labeled bone surfaces.
(36) Therefore, we believe that measurement of genetically labeled cell thickness perpendicular to bone surfaces does serve as a reasonable proxy measure for osteoblast activation.
Mechanisms other than lining cell reactivation may account for Scl-Ab-induced increases in osteoblast number, particularly with extended treatment duration. It is likely that Scl-Ab-activated lining cells would become embedded as osteocytes in new bone matrix and require additional precursor recruitment to continue bone f o r m a t i o no nag i v e ns u r f a c e .T h a tb e i n gs a i d ,w eh a v en o t prospectively followed the fate of Scl-Ab-activated lining cells over time. With chronic administration, the Scl-Ab-mediated increases in bone formation are not sustained, which have been associated with changes in osteocyte gene expression and decreases in osteoprogenitor numbers. (35) Reduced apoptosis of existing osteoblasts and stimulation of early pools of osteoblast precursors may participate as well. One interesting hypothesis thatemergesfromthisworkisthat waning Scl-Ab efficacy over time is attributable to a dwindling reserve pool of quiescent lining cells that can be activated after repeated Scl-Ab administration. Definitive studies of the effects of Scl-Ab on osteoprogenitor populations will require use of advanced technologies such as flow cytometry and lineage tracing designed to identify, profile, and track such cells over time during the response to Scl-Ab administration.
Using both transgenic lineage-tracing models, we observed an apparent increase in the number of labeled cells on bone surfaces after Scl-Ab treatment. This was not accompanied by an obvious increase in cell proliferation (measured by BrdU and EdU incorporation) or a decrease in apoptosis. Changes in these parameters may occur below the detection limits of the methods used. An alternative possibility may be that our detection method for labeled cells on two-dimensional sections is biased toward detection of large cells. Because Scl-Ab clearly increases the size of labeled cells, the increase in cell numbers observed may reflect a technical limitation of our approach rather than a true increase in cell number. Future studies using three-dimensional detection methods (36, 37) will be required to resolve this important issue. The precise identity of the reticular-appearing bone marrow cells labeled in osteocalcin-CreERt2:Ai9 mice remains elusive. These cells do not express high levels of osteocalcin, as evident by lack of GFP expression in osteocalcin-GFP:osteocalcin-CreERt2: Ai9 tri-transgenic mice 2 days after tamoxifen administration (not shown). This finding does not exclude low osteocalcin expression or ectopic expression of the osteocalcin-CreERt2 transgene. These cells are not actively dividing (Supplemental Fig. S4A ), and numbers of these cells are not affected by Scl-Ab treatment (Supplemental Fig. S4D ). Therefore, it is unlikely that these cells provide a major contribution to the pool of tdTomato-positive osteoblasts observed after Scl-Ab treatment. Furthermore, because Scl-Ab also increases the thickness of labeled periosteal cells, we believe that it is extremely unlikely that these bone marrow reticular cells could migrate across cortical bone to contribute to this population of new osteoblasts. A distinct, and equally unlikely, possibility to explain these results could be that Scl-Ab treatment could cause labeled osteocytes to dedifferentiate into active osteoblasts. Indeed, this phenomenon has been described to occur in ex vivo bone chip explant cultures. (38) Overall numbers of X-gal and tdTomatopositive osteocytes are not decreased after brief Scl-Ab treatment (not shown), and osteocyte dedifferentiation into osteoblasts has not been reported to occur under physiologic in vivo settings.
These findings highlight an inherent limitation associated with in vivo lineage-tracing studies. If the promoter upstream of a given CreERt2 (or Cre) transgene is initially active in a heterogeneous population of cells, it is difficult to unambiguously identify the source of a labeled cell at the end of a chase period. Just as osteocalcin-driven CreERt2 (our findings) and osteocalcinCre (31) label non-osteoblasts, the commonly used osterix-Cre transgene has been reported to target multiple cell types outside the osteoblast lineage postnatally. (39) Nonetheless, our data here using in vivo lineage tracing in mice are completely consistent with previous results in rats and cynomolgus monkeys suggesting that Scl-Ab increases osteoblast number in part via converting quiescent lining cells into osteoblasts.
The therapeutic efficacy of both intermittent PTH and Scl-Ab wanes with time, albeit with differing kinetics. (18, 40) An appealing hypothesis to account for some of this pattern could be that both treatments quickly consume the pool of quiescent lining cells poised to become osteoblasts. A detailed understanding of how lining cells develop and are subsequently activated will be required to design new agents to enable persistent increases in osteoblastic activity.
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